RCS - Avacta Group PLC - Notice of Investor Presentation

AvactaAnnouncement

Thu 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251023:nRSW6352Ea&default-theme=true

RNS Number : 6352E  Avacta Group PLC  23 October 2025

 

Notice of Investor Presentation

 

LONDON and PHILADELPHIA - October 23, 2025 - Avacta Therapeutics (AIM: AVCT,
'Avacta', 'the Company'), a clinical stage biopharmaceutical company
developing pre|CISION(®), a unique oncology delivery platform, announces the
team will present the published data of the platform innovation, the
pre|CISION(®) dual payload peptide drug conjugate (PDC) delivery system,
following their return from the 2025 AACR-NCI-EORTC International Molecular
Targets Congress.

 

Christina Coughlin, Chief Executive Officer, David Liebowitz, Chief Medical
Officer, Francis Wilson, VP Chemistry and Ruairidh Edwards, Translational
Scientist will deliver a presentation via Investor Meet Company at 16:00 BST
on Wednesday October 29, 2025.

 

The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and add to meet AVACTA
GROUP PLC here
(https://www.investormeetcompany.com/avacta-group-plc/register-investor) .

 

Investors who already follow Avacta on the Investor Meet Company platform will
automatically be invited.

 

Questions can be submitted pre-event via the Investor Meet Company dashboard
up until October 28 09:00 BST, or at any time during the recorded
presentation.

 

 

-Ends-

 

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                           https://avacta.com/ (https://avacta.com/)

 Christina Coughlin (CEO), Brian Hahn (CFO)

 Peel Hunt (Nomad and Broker)                                www.peelhunt.com (http://www.peelhunt.com)

 James Steel / Chris Golden

 Panmure Liberum (Joint Broker)                             www.panmureliberum.com (http://www.panmureliberum.com)

 Emma Earl / Will Goode / Mark Rogers

 Zeus (Joint Broker)                                        www.zeuscapital.co.uk (http://www.zeuscapital.co.uk/)

 James Hornigold / George Duxberry

 Dominic King

 ICR Healthcare

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert   avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Investor Contact                                           renee@thrustsc.com (mailto:renee@thrustsc.com)

 Renee Leck

 THRUST Strategic Communications

 Media Contact                                               carly@thrustsc.com (mailto:carly@thrustsc.com)

 Carly Scaduto

 THRUST Strategic Communications

 

 

About Avacta - www.avacta.com
(https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.avacta.com%2F&data=05%7C02%7CChris.Coughlin%40avacta.com%7Ce5faa8dfbe3d49fc56f808dd35799958%7C64d2165ff9e04869bc73bfe4fc4fa9ab%7C0%7C0%7C638725518576703790%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=qWTC74zmTzjVQqwaFiKeiHUwMY5RUlsvb7C%2BkLRahGU%3D&reserved=0)

Avacta is a clinical stage life sciences company developing an innovative
proprietary drug delivery peptide drug conjugate (PDC) platform,
pre|CISION(®). The pre|CISION(®) platform uniquely enables the repurposing
of a range of oncology drugs as PDC payloads with the goal to significantly
reduce toxicity and side effects for patients by concentrating the drug
directly in the tumor.

 

About pre|CISION(®)

 

The key aspect of pre|CISION(®) is its peptide drug conjugates (PDC)
technology. The combination of the cancer drug and the proprietary cleavable
peptide (the PDC) is inert and incapable of entering cells and killing them
until the peptide is specifically released within the tumor. The active
payload in the pre|CISION(®) PDC is released when the PDC comes into contact
with the common tumor-associated protein, known as fibroblast activation
protein (FAP), in the tumor. The release of the payload from the
pre|CISION(®) product directly in the tumor results in higher concentration
of the drug at the tumor and lower blood and healthy tissue levels than
standard systemic administration, offering the potential to improve efficacy
and patient tolerability.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFZMZGKFRGKZM



            Copyright 2019 Regulatory News Service, all rights reserved